{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:42:09Z","timestamp":1788871329234,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.lungcan.2025.108436","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T11:20:52Z","timestamp":1738668052000},"page":"108436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Brain metastases and mortality in patients with ALK\u00a0+\u00a0metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study"],"prefix":"10.1016","volume":"201","author":[{"given":"Dipesh","family":"Uprety","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Abrahami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary A.","family":"Marcum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7627-9519","authenticated-orcid":false,"given":"Nada","family":"Rifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3308-0276","authenticated-orcid":false,"given":"John M.","family":"Kelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnan","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parag","family":"Sanghvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmila","family":"Bazhenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108436_b0005","unstructured":"American Cancer Society. What Is Lung Cancer? 2024. (Updated: January 29, 2024) Available at: https:\/\/www.cancer.org\/cancer\/lung-cancer\/about\/what-is.html. Accessed: May 17, 2024."},{"key":"10.1016\/j.lungcan.2025.108436_b0010","unstructured":"SEER. Lung and Bronchus Cancer - Stage Distribution of SEER Incidence Cases, 2008-2021. November 2023. Available at: https:\/\/seer.cancer.gov\/explorer\/application.html?site=47&data_type=1&graph_type=4&compareBy=sex&chk_sex_1=1&chk_sex_3=3&chk_sex_2=2&race=1&age_range=1&advopt_precision=1&advopt_toggle_transpose=on&advopt_display=2#tableWrap. Accessed: May 17, 2024."},{"key":"10.1016\/j.lungcan.2025.108436_b0015","doi-asserted-by":"crossref","first-page":"E152","DOI":"10.21037\/jtd.2017.02.05","article-title":"Alectinib for the management of ALK-positive non-small cell lung cancer brain metastases","volume":"9","author":"Lockney","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2025.108436_b0020","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108436_b0025","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/JCO.23.02744","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2023.3","volume":"42","author":"Jaiyesimi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108436_b0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.lungcan.2025.108436_b0035","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108436_b0040","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non\u2013small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108436_b0045","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108436_b0050","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lungcan.2025.108436_b0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ctrv.2016.03.009","article-title":"The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer","volume":"45","author":"Peters","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2025.108436_b0060","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108436_b0065","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtho.2018.07.001","article-title":"The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib","volume":"13","author":"Patil","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108436_b0070","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cllc.2022.09.007","article-title":"Real-world treatment sequencing, toxicities, health utilities, and survival outcomes in patients with advanced ALK-rearranged non-small-cell lung cancer","volume":"24","author":"Schmid","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108436_b0075","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-na\u00efve advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108436_b0080","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.cllc.2022.07.008","article-title":"Efficacy and safety of brigatinib compared with crizotinib in Asian vs. non-Asian patients with locally advanced or metastatic ALK-inhibitor-na\u00efve ALK+ non-small cell lung cancer: final results from the phase III ALTA-1L study","volume":"23","author":"Ahn","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108436_b0085","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.lungcan.2025.108436_b0090","first-page":"01199","article-title":"National enrollment of lung cancer clinical trials is disproportionate based on race and health care access","volume":"S0022-5223","author":"Kwak","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.lungcan.2025.108436_b0095","doi-asserted-by":"crossref","first-page":"882","DOI":"10.7326\/M23-2480","article-title":"Association of Medicare Advantage enrollment with financial burden of care: a retrospective cohort study","volume":"177","author":"Park","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.lungcan.2025.108436_b0100","unstructured":"STROBE Checklists. https:\/\/www.strobe-statement.org\/checklists\/, 2024. Accessed: June 30, 2024."},{"key":"10.1016\/j.lungcan.2025.108436_b0105","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11060-009-9943-z","article-title":"Utility of administrative claims data for the study of brain metastases: a validation study","volume":"95","author":"Eichler","year":"2009","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.lungcan.2025.108436_b0110","unstructured":"ResDAC, Death Information in the Research Identifiable Medicare Data. https:\/\/resdac.org\/articles\/death-information-research-identifiable-medicare-data, 2022. Accessed: June 15, 2024."},{"key":"10.1016\/j.lungcan.2025.108436_b0115","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"10.1016\/j.lungcan.2025.108436_b0120","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40801-021-00269-0","article-title":"Comparison between health insurance claims and electronic health records (EHRs) for metastatic non-small-cell lung cancer (NSCLC) patient characteristics and treatment patterns: a retrospective cohort study","volume":"8","author":"Choi","year":"2021","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.lungcan.2025.108436_b0125","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.lungcan.2025.108436_b0130","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jama.2020.1021","article-title":"Mortality and hospitalizations for dually enrolled and nondually enrolled Medicare beneficiaries aged 65 years or older, 2004 to 2017","volume":"323","author":"Wadhera","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.lungcan.2025.108436_b0135","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.lungcan.2018.03.008","article-title":"Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer","volume":"119","author":"Burudpakdee","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108436_b0140","doi-asserted-by":"crossref","first-page":"P2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK-inhibitor-na\u00efve advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thor. Oncol."},{"key":"10.1016\/j.lungcan.2025.108436_b0145","unstructured":"FDA Guidance Document, Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies?utm_medium=email&utm_source=govdelivery, 2024. Accessed: July 7, 2024."},{"key":"10.1016\/j.lungcan.2025.108436_b0150","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.21037\/jtd-20-3450","article-title":"Sociodemographic disparities in the management of advanced lung cancer: a narrative review","volume":"13","author":"Stein","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2025.108436_b0155","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s11910-023-01314-x","article-title":"Disparities in neuro-oncology","volume":"23","author":"Michaelson","year":"2023","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.lungcan.2025.108436_b0160","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.2214\/AJR.21.25787","article-title":"Development of brain metastases in patients with non-small cell lung cancer and no brain metastases at initial staging evaluation: cumulative incidence and risk factor analysis","volume":"217","author":"Kim","year":"2021","journal-title":"AJR Am. J. Roentgenol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225000571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225000571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T05:44:31Z","timestamp":1743831871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225000571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":32,"alternative-id":["S0169500225000571"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108436","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain metastases and mortality in patients with ALK\u00a0+\u00a0metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108436"}}